Literature DB >> 19054920

Treatment with high-dose methylprednisolone for hepatic veno-occlusive disease in a child with rhabdomyosarcoma.

I-Lun Chen1, San-Nan Yang, Chih-Cheng Hsiao, Kuan-Sheng Wu, Jiunn-Ming Sheen.   

Abstract

Hepatic veno-occlusive disease (VOD), also called sinusoidal obstruction syndrome, is rapidly progressing and involves life-threatening complications that can occur in patients receiving chemotherapy and/or bone marrow transplantation. No completely satisfactory treatmentstrategies have yet been established. We present a case of rhabdomyosarcoma ina 21-month-old boy who developed pancytopenia, dyspnea, jaundice, massive ascites and body weight gain of more than 10% after receiving conventional chemotherapy. Hepatic VOD was diagnosed. He recovered after supportive care and treatment with high-dose methylprednisolone.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19054920     DOI: 10.1016/S1875-9572(08)60029-7

Source DB:  PubMed          Journal:  Pediatr Neonatol        ISSN: 1875-9572            Impact factor:   2.083


  3 in total

Review 1.  Hepatic veno-occlusive disease: a chemotherapy-related toxicity in children with malignancies.

Authors:  Maria Giuseppina Cefalo; Palma Maurizi; Annalisa Arlotta; Maria Scalzone; Giorgio Attinà; Antonio Ruggiero; Riccardo Riccardi
Journal:  Paediatr Drugs       Date:  2010-10-01       Impact factor: 3.022

2.  High-dose methylprednisolone for veno-occlusive disease of the liver in pediatric hematopoietic stem cell transplantation recipients.

Authors:  Kasiani C Myers; Julia Lawrence; Rebecca A Marsh; Stella M Davies; Sonata Jodele
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-01       Impact factor: 5.742

Review 3.  Hepatic sinusoidal obstruction syndrome during chemotherapy for childhood medulloblastoma: report of a case and review of the literature.

Authors:  Rishi S Kotecha; Amy Buckland; Marianne B Phillips; Catherine H Cole; Nicholas G Gottardo
Journal:  J Pediatr Hematol Oncol       Date:  2014-01       Impact factor: 1.289

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.